PMID- 16912221 OWN - NLM STAT- MEDLINE DCOM- 20070117 LR - 20211203 IS - 0006-4971 (Print) IS - 0006-4971 (Linking) VI - 108 IP - 13 DP - 2006 Dec 15 TI - Syk-dependent mTOR activation in follicular lymphoma cells. PG - 4156-62 AB - The mammalian target of rapamycin (mTOR) is emerging as a promising target for antitumor therapy. However, the mechanism that contributes to its regulation in B lymphomas remains unknown. This study shows that in follicular lymphoma (FL) cells, mTOR is active because the cells displayed rapamycin-sensitive phosphorylation of p70S6 kinase and 4E-BP1. Moreover, immunohistochemistry applied on lymph node tissue sections obtained from patients with FL revealed that, in most cases, p70S6 kinase was highly phosphorylated compared to normal tonsillar tissue. In FL cells, mTOR was under control of both phospholipase D (PLD) and phosphatidylinositol 3-kinase (PI3K). Moreover, we demonstrated that Syk plays a central role in mTOR activation because we found that both expression and activity are elevated compared to normal or chronic lymphocytic leukemia B cells. We also provide evidence that Syk operates through PLD- and PI3K-independent pathways. Finally, Syk inhibition by piceatannol or by siRNA plasmids resulted in a potent inhibition of mTOR activity in FL cells, as well as in mantle cell lymphoma, Burkitt lymphoma, and diffuse large B-cell lymphoma. These findings suggest that the Syk-mTOR pathway has a critical function in FL survival, and therefore, that Syk could be a promising new target for B-lymphoma therapy. FAU - Leseux, Ludivine AU - Leseux L AD - INSERM U563-Centre de Physiopathologie Toulouse Purpan (CPTP), Departement d'Oncogenese et Signalisation dans les Cellules Hematopoietiques, Centre Hospitalier Universitaire (CHU) Purpan-BP3028, Toulouse, France. FAU - Hamdi, Safouane M AU - Hamdi SM FAU - Al Saati, Talal AU - Al Saati T FAU - Capilla, Florence AU - Capilla F FAU - Recher, Christian AU - Recher C FAU - Laurent, Guy AU - Laurent G FAU - Bezombes, Christine AU - Bezombes C LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060815 PL - United States TA - Blood JT - Blood JID - 7603509 RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (Neoplasm Proteins) RN - 0 (RNA, Small Interfering) RN - 0 (Stilbenes) RN - 6KS3LS0D4F (3,3',4,5'-tetrahydroxystilbene) RN - EC 2.7.- (Protein Kinases) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) RN - EC 2.7.10.2 (SYK protein, human) RN - EC 2.7.10.2 (Syk Kinase) RN - EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - EC 3.1.4.4 (Phospholipase D) SB - IM MH - Burkitt Lymphoma/drug therapy/enzymology/pathology MH - Cell Line, Tumor MH - Enzyme Activation/drug effects MH - Humans MH - Intracellular Signaling Peptides and Proteins/*metabolism MH - Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/enzymology/pathology MH - Lymph Nodes/metabolism/pathology MH - Lymphoma, B-Cell/drug therapy/enzymology/pathology MH - Lymphoma, Follicular/drug therapy/*enzymology/pathology MH - Lymphoma, Mantle-Cell/drug therapy/enzymology/pathology MH - Neoplasm Proteins/*metabolism MH - Palatine Tonsil/enzymology/metabolism MH - Phosphatidylinositol 3-Kinases/metabolism MH - Phospholipase D/metabolism MH - Protein Kinases/*metabolism MH - Protein-Tyrosine Kinases/*metabolism MH - RNA, Small Interfering/genetics/pharmacology MH - Ribosomal Protein S6 Kinases, 70-kDa/metabolism MH - *Signal Transduction/drug effects MH - Stilbenes/pharmacology MH - Syk Kinase MH - TOR Serine-Threonine Kinases EDAT- 2006/08/17 09:00 MHDA- 2007/01/18 09:00 CRDT- 2006/08/17 09:00 PHST- 2006/08/17 09:00 [pubmed] PHST- 2007/01/18 09:00 [medline] PHST- 2006/08/17 09:00 [entrez] AID - S0006-4971(20)52213-1 [pii] AID - 10.1182/blood-2006-05-026203 [doi] PST - ppublish SO - Blood. 2006 Dec 15;108(13):4156-62. doi: 10.1182/blood-2006-05-026203. Epub 2006 Aug 15.